ArticleDiabetology & metabolic syndrome2025
Impact of changes in diabetes care models and advanced technologies on two-year glycemic control after COVID-19 lockdown in adults with Type 1 Diabetes.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe COVID-19 pandemic led to significant shifts in lifestyle and clinical management for individuals with Type 1 Diabetes (T1D) that, during the COVID-19 lockdown, showed an improved glycemic control, characterized by increased time-in-range (TIR) and reduced glucose variability. This study aimed to assess the long-term trends and factors influencing glycemic control over two years post-lockdown in adults with T1D.
methodsA longitudinal study was conducted on 207 adults with T1D (mean age 38 ± 13 years), with 50.2% using multiple daily insulin injections and 49.8% on continuous subcutaneous insulin infusion. Continuous glucose monitoring (CGM) metrics-including TIR, time-above-range (TAR); time-below-range (TBR), and coefficient of variation (CV)- were assessed before, during, and at 6, 12, and 24 months post-lockdown. Participants also completed an online questionnaire evaluating lifestyle habits before, during, and one year after lockdown.
resultsThe glycemic improvements observed during lockdown persisted for two years. TIR 70-180 mg/dl remained significantly higher, while TAR > 250 mg/dl and TBR < 54 mg/dl were significantly lower at all post-lockdown time points (p < 0.05 for all). These improvements were not attributed to lifestyle changes, which remained relatively stable one year after lockdown. Telemedicine was implemented being the prevalent model of care during this period. Notably, the improvement in glycemic control concerned the participants transitioning to advanced insulin delivery systems during the two-year observational period (p < 0.001).
conclusionsGlycemic control improvements in adults with T1D were sustained for two years post-lockdown and related to transitioning to more advanced insulin delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.